Stryker Co. (NYSE:SYK) Stock Holdings Cut by Schwartz Investment Counsel Inc.

Schwartz Investment Counsel Inc. reduced its position in shares of Stryker Co. (NYSE:SYKFree Report) by 2.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,950 shares of the medical technology company’s stock after selling 42 shares during the quarter. Schwartz Investment Counsel Inc.’s holdings in Stryker were worth $702,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Chicago Capital LLC boosted its holdings in shares of Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company’s stock worth $70,228,000 after buying an additional 5,841 shares during the period. Zhang Financial LLC raised its stake in Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock valued at $41,366,000 after purchasing an additional 40,784 shares during the period. Appleton Partners Inc. MA lifted its holdings in shares of Stryker by 5.0% in the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company’s stock valued at $10,521,000 after purchasing an additional 1,400 shares in the last quarter. Dale Q Rice Investment Management Ltd acquired a new stake in shares of Stryker in the fourth quarter worth $587,000. Finally, Berkshire Bank grew its holdings in shares of Stryker by 13.8% during the fourth quarter. Berkshire Bank now owns 8,489 shares of the medical technology company’s stock valued at $3,056,000 after buying an additional 1,030 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $390.52 on Wednesday. The business’s 50 day moving average is $377.28 and its 200-day moving average is $365.59. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $148.88 billion, a PE ratio of 50.33, a PEG ratio of 2.98 and a beta of 0.96. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYKGet Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the business posted $3.46 earnings per share. Sell-side analysts predict that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SYK. Stifel Nicolaus increased their price objective on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. BTIG Research upped their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group lifted their target price on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research note on Thursday, January 30th. UBS Group upped their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Finally, Barclays boosted their target price on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $420.68.

Read Our Latest Stock Report on SYK

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Further Reading

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.